ProCE Banner Activity

What Will Be the Place of JAK Inhibitors in the New ACR 2020 Pharmacologic Recommendations for the Management of RA?

Clinical Thought
The new guidelines may level the playing field between TNF inhibitors and JAK inhibitors.

Released: December 23, 2020

Expiration: December 22, 2021

No longer available for credit.

Share

Faculty

Stanley B. Cohen

Stanley B. Cohen, MD

Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director
Division of Rheumatology
Presbyterian Hospital
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Gilead

Faculty Disclosure

Primary Author

Stanley B. Cohen, MD

Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director
Division of Rheumatology
Presbyterian Hospital
Dallas, Texas

Stanley B. Cohen, MD, has disclosed that he has received consulting fees from AbbVie, Gilead Sciences, and Pfizer, and funds for research support from AbbVie, Gilead Sciences, Lilly, and Pfizer.